The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Researchers are exploring cancer drugs as a potential treatment for Alzheimer's disease, a neurodegenerative disorder with limited treatment options. Studies have identified two cancer drugs, ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce ...

We all forget things. Names, dates, phone chargers – even why we walked into the kitchen. It’s called being human… or, let’s be honest, being over 40 in a digital world with too many tabs open in our ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...